Education
About Us
Working with TipRanks
Follow Us
Artrya Limited (AU:AYA)
ASX:AYA
AYA Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.20 - AU$1.04
Previous CloseN/A
Volume107.30K
Average Volume (3M)314.64K
Market Cap
N/A
Enterprise ValueAU$10.97M
Total Cash (Recent Filing)AU$12.98M
Total Debt (Recent Filing)AU$10.00K
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Aug 28, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding99,006,060
10 Day Avg. Volume588,667
30 Day Avg. Volume314,645
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$2.26Price Target Upside213.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Artrya Limited News
PremiumCompany Announcements
Artrya Limited Successfully Passes All Resolutions at General MeetingPremiumCompany Announcements
Artrya Limited Announces Quotation of New Securities on ASX
PremiumCompany Announcements
Artrya Limited Issues Shares on Performance Rights Conversion
PremiumCompany Announcements
Artrya Limited Secures FDA Clearance for Salix® Coronary Anatomy
PremiumCompany Announcements
Artrya Limited Announces Quotation of New Securities on ASX
PremiumCompany Announcements
Artrya Limited Issues Shares Following Performance Rights Conversion
PremiumCompany Announcements
Artrya Limited Announces Quotation of New Securities on ASX---
AYA FAQ
What was Artrya Limited’s price range in the past 12 months?
Artrya Limited lowest share price was AU$0.20 and its highest was AU$1.04 in the past 12 months.
What is Artrya Limited’s market cap?
Currently, no data Available
When is Artrya Limited’s upcoming earnings report date?
Artrya Limited’s upcoming earnings report date is Aug 28, 2025 which is in 145 days.
How were Artrya Limited’s earnings last quarter?
Artrya Limited released its earnings results on Feb 24, 2025. The company reported -AU$0.091 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.091.
Is Artrya Limited overvalued?
According to Wall Street analysts Artrya Limited’s price is currently Undervalued.
Does Artrya Limited pay dividends?
Artrya Limited does not currently pay dividends.
What is Artrya Limited’s EPS estimate?
Artrya Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Artrya Limited have?
Artrya Limited has 99,006,060 shares outstanding.
What happened to Artrya Limited’s price movement after its last earnings report?
Artrya Limited reported an EPS of -AU$0.091 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.235%.
Which hedge fund is a major shareholder of Artrya Limited?
Currently, no hedge funds are holding shares in AU:AYA
---
Artrya Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$2.26 (213.89% Upside)
AU$2.26 (213.89% Upside)
Blogger Sentiment
Bullish
AU:AYA Sentiment 100%
Sector Average 69%
Sector Average 69%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
132.30%
12-Months-Change
Fundamentals
Return on Equity
-75.75%
Trailing 12-Months
Asset Growth
-36.14%
Trailing 12-Months
Company Description
Artrya Limited
Artrya Limited operates as a medical technology company that uses artificial intelligence (AI) to identify patients at risk of coronary artery disease. It offers Salix, a cloud-based software that uses its AI to automate the detection of coronary artery disease from coronary computed tomography angiography. The company was incorporated in 2018 and is based in West Perth, Australia.
---
AYA Stock 12 Month Forecast
Average Price Target
AU$2.26
▲(213.89% Upside)
Technical Analysis
CardieX Limited
―
Biotron Limited
―
Imugene Limited
―
Race Oncology Ltd.
―
Cyclopharm Limited
―
Best Analysts Covering AYA
1 Year
1 Year Success Rate
1/3 ratings generated profit
1 Year Average Return
+28.53%
reiterated a buy rating 8 days ago
Copying Tanushree Jain's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +28.53% per trade.
---